PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI